Craif Inc. (headquartered in Shinjuku-ku, Tokyo; CEO: Ryuichi Onose; hereinafter "Craif"), a bio-AI startup, will begin providing the urine-based cancer risk test "MySignal" through a publicly funded program utilizing subsidies in collaboration with Shinjo Village, Mimasaka District, Okayama Prefecture (Village Mayor: Hirohito Ogura), starting August 2026. This initiative, implemented at zero cost to residents, is positioned as a demonstration project to establish a new model for early cancer detection, with the aim of evaluating potential for ongoing implementation and expansion of eligibility. "MySignal" is a test that uses bio-AI technology to assess cancer risk for 10 types of cancer from Stage 1. Through this project, Craif aims to build a scalable social model for early cancer detection in regions facing healthcare access challenges and expand it nationwide. ■ Background of the Initiative In Japan, one in two people will develop cancer, and cancer screening participation rates remain low at around 40%—a figure below international standards. Particularly in rural areas with limited access to medical facilities, these structural barriers further suppress screening rates. In Shinjo Village, Okayama Prefecture, residents often face travel times of over 30 minutes by car to reach nearby medical facilities, and daily life demands frequently lead to delayed screenings, resulting in participation rates below the national average. Preventing disease progression and rising medical costs due to late detection has become an urgent priority. As one response to these regional challenges, Shinjo Village will implement a publicly funded program utilizing subsidies, enabling selected residents to take the "MySignal" test at no personal cost. Craif will collaborate with the village to advance the societal implementation of early cancer detection through the provision of MySignal. ◾ Overview of the Shinjo Village MySignal Project Approximately 30 residents of Shinjo Village, Oka